+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Seasonal Influenza Vaccines

  • ID: 4335315
  • Report
  • January 2019
  • Region: Global
  • 123 Pages
  • Datamonitor Healthcare
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
Global Vaccination Rates Remain Lower than the Levels Recommended by the World Health Organization
Disease Overview
Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates. Seasonal influenza can be type A, B, or C. Type A influenza viruses are considered to be the most virulent of the three types, and can be further classified by serotype based on antibody response to the virus.

Market Snapshot
  • Conversion to quadrivalent influenza vaccines will drive market growth.
  • Differentiated vaccines targeting specific population subgroups will see significant uptake.
  • Universal flu vaccines could gain rapid uptake if they can show efficacy against multiple influenza strains.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: SEASONAL INFLUENZA VACCINES
Overview
Recent Forecast Updates
Market Overview And Trends
Key Drivers And Resistors Of Conversion To Qivs
Market Definition And Methodology
Us Market Forecast
France Market Forecast
Germany Market Forecast
Italy Market Forecast
Spain Market Forecast
Uk Market Forecast
Primary Research Methodology

MARKETED DRUGS: SEASONAL INFLUENZA VACCINES (Published on 10 January 2019)
Overview
Product Overview
Inactivated Vaccines
Product Profile: Flumist Qiv
Product Profile: Flublok
Product Profile: Flucelvax Qiv
Product Profile: Fluzone High-Dose

PIPELINE: SEASONAL INFLUENZA VACCINES (Published on 10 January 2019)
Overview
Clinical Pipeline Overview
Universal Influenza Vaccines
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Fluad Qiv
Product Profile (Late Stage): Mt-2271

LIST OF FIGURES
Figure 1: Total sales of seasonal influenza vaccines across the US and five major EU markets, by country, 2017/18–2026/27
Figure 2: Total sales of seasonal influenza vaccines across the US and five major EU markets, by class, 2017/18–2026/27
Figure 3: Patient-based forecasting methodology for seasonal influenza vaccines
Figure 4: Price sources and calculations in the EU, by country
Figure 5: Total sales of seasonal influenza vaccines in the US, by class, 2017/18–2026/27
Figure 6: Total seasonal influenza vaccination coverage in the US, by risk group, 2017/18–2026/27
Figure 7: Total sales of seasonal influenza vaccines in France, by class, 2017/18–2026/27
Figure 8: Total seasonal influenza vaccination coverage in France, by risk group, 2017/18–2026/27
Figure 9: Total sales of seasonal influenza vaccines in Germany, by class, 2017/18–2026/27
Figure 10: Total seasonal influenza vaccination coverage in Germany, by risk group, 2017/18–2026/27
Figure 11: Total sales of seasonal influenza vaccines in Italy, by class, 2017/18–2026/27
Figure 12: Total seasonal influenza vaccination coverage in Italy, by risk group, 2017/18–2026/27
Figure 13: Total sales of seasonal influenza vaccines in Spain, by class, 2017/18–2026/27
Figure 14: Total seasonal influenza vaccination coverage in Spain, by risk group, 2017/18–2026/27
Figure 15: Total sales of seasonal influenza vaccines in the UK, by class, 2017/18–2026/27
Figure 16: Total seasonal influenza vaccination coverage in the UK, by risk group, 2017/18–2026/27

LIST OF TABLES
Table 1: Recommendations for influenza vaccination by national authorities, by country, 2018–19
Table 2: Key drivers and resistors of conversion to QIVs
Table 3: Exchange rates used for calculating prices
Table 4: Total influenza coverage rates in the US compared to the five major EU markets, 2017/18–2026/27
Table 5: Profiled key marketed vaccines for seasonal influenza
Table 6: Inactivated vaccines class overview
Table 7: Inactivated vaccines for seasonal influenza – SWOT analysis
Table 8: FluMist QIV drug profile
Table 9: Approval history of FluMist QIV for seasonal influenza vaccination in the US and five major EU markets
Table 10: Late-phase trials of FluMist QIV for seasonal influenza vaccination
Table 11: FluMist QIV for seasonal influenza – SWOT analysis
Table 12: Flublok drug profile
Table 13: Approval history of Flublok for seasonal influenza vaccination
Table 14: Late-phase trials of Flublok for seasonal influenza vaccination
Table 15: Flublok for seasonal influenza – SWOT analysis
Table 16: Flucelvax QIV drug profile
Table 17: Approval history of Flucelvax for seasonal influenza vaccination
Table 18: Late-phase trials of Flucelvax QIV for seasonal influenza vaccination
Table 19: Flucelvax QIV for seasonal influenza – SWOT analysis
Table 20: Fluzone High-Dose drug profile
Table 21: Approval history of Fluzone HD for seasonal influenza vaccination
Table 22: Late-phase trials of Fluzone HD for seasonal influenza vaccination
Table 23: Fluzone High-Dose for seasonal influenza – SWOT analysis
Table 24: Profiled pipeline products in development for seasonal influenza
Table 25: Universal influenza vaccines class overview
Table 26: Clinical trials of M-001 for seasonal influenza vaccination
Table 27: Clinical trials of Flu-v for seasonal influenza vaccination
Table 28: Clinical trials of MVA-NP+M1 for seasonal influenza vaccination
Table 29: Universal influenza vaccines for seasonal influenza – SWOT analysis
Table 30: Fluad QIV drug profile
Table 31: Late-phase trials of Fluad QIV for seasonal influenza vaccination
Table 32: Fluad QIV for seasonal influenza – SWOT analysis
Table 33: MT-2271 drug profile
Table 34: Clinical trials of MT-2271 for seasonal influenza vaccination
Table 35: MT-2271 for seasonal influenza – SWOT analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

Adroll
adroll